| Bioactivity | Libivirumab (17.1.41) is a humanized anti-HBV monoclonal antibody. Libivirumab shows neutralization activity with IC50s of 35, 130 ng/mL for HBsAg, HBeAg, respectively[1]. |
| Invitro | Libivirumab (0-500 ng/mL) shows neutralization activity in HepG2-NTCP cells with IC50s of 35, 130 ng/mL for HBsAg, HBeAg, respectively[1]. |
| Name | Libivirumab |
| CAS | 569658-79-3 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Wang Q, et al. A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations. Cell Host Microbe. 2020 Aug 12;28(2):335-349.e6. |